Actively Recruiting
IL-6: A Marker for AML Chemo Sensitivity
Led by Fujian Medical University Union Hospital · Updated on 2024-07-03
72
Participants Needed
1
Research Sites
87 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Acute myeloid leukemia (AML) is a clonal malignancy that arises from the primitive hematopoietic cells within the hematopoietic system. According to SEER cancer statistics, the 5-year survival rate for AML patients stands at a concerning 30%. Despite therapeutic advancements, the development of chemotherapy resistance and the risk of disease relapse pose significant barriers to curative outcomes. Evidence has linked elevated interleukin-6 (IL-6) levels in plasma and bone marrow to a poorer prognosis in AML, with IL-6 potentially fostering chemotherapy resistance through the enhancement of fatty acid uptake and the induction of stromal-like morphological changes in AML cells. However, the role of IL-6 as a potential biomarker for monitoring chemotherapy sensitivity in AML has not been fully elucidated. This study seeks to investigate the correlation between IL-6 levels in bone marrow supernatant and the sensitivity to chemotherapy, offering a clinical perspective that could pave the way for improved prognostic markers and personalized treatment strategies.
CONDITIONS
Official Title
IL-6: A Marker for AML Chemo Sensitivity
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinical diagnosis follows Chinese guidelines for adult AML (not APL) (2023)
- Patients are experiencing their first onset of AML
- No prior chemotherapy received for AML
- Participation with family members and signed informed consent
You will not qualify if you...
- Patients with other malignancies requiring treatment
- Presence of infectious diseases including SARS, viral hepatitis, or HIV/AIDS
- Major surgery within the last 21 days
- Performance status score greater than 3
- Severe liver or kidney dysfunction or serious infection
- Severe psychiatric conditions affecting understanding or voluntary participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fujian Medical University Union Hospital
Fuzhou, Fujian, China, 350001
Actively Recruiting
Research Team
H
Huifang Huang
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here